Takahashi M, Furukawa F, Miyakawa Y, Sato H, Hasegawa R, Hayashi Y
Jpn J Cancer Res. 1986 Jun;77(6):509-13.
In two separate experiments, 2.0 mg of 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) was applied to the back of female CD-1 mice twice weekly for 5 weeks followed by application of 2.5 micrograms of 12-O-tetradecanoyl-phorbol-13-acetate (TPA) twice weekly for 47 weeks. Skin squamous cell papillomas and carcinomas developed in 6 of 20 mice (30%) in Experiment 1 and in 3 of 19 mice (16%) in Experiment 2. In contrast, application of 2.0 mg of Trp-P-2 twice weekly for 52 weeks did not produce any skin tumors. These data suggest that Trp-P-2 acts primarily as an initiator, not as a complete carcinogen, for mouse skin.
在两项独立实验中,每周两次给雌性CD-1小鼠背部涂抹2.0毫克的3-氨基-1-甲基-5H-吡啶并[4,3-b]吲哚(Trp-P-2),持续5周,随后每周两次涂抹2.5微克的12-O-十四烷酰佛波醇-13-乙酸酯(TPA),持续47周。在实验1的20只小鼠中有6只(30%)出现了皮肤鳞状细胞乳头状瘤和癌,在实验2的19只小鼠中有3只(16%)出现了此类情况。相比之下,每周两次涂抹2.0毫克Trp-P-2,持续52周,未产生任何皮肤肿瘤。这些数据表明,Trp-P-2对小鼠皮肤主要起引发剂作用,而非完全致癌物作用。